AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03910491 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PriCARE
Description: PriCARE is a group parent training program designed to improve child behavior, improve parent-child relationships, and decrease stress for parents. PriCARE emphasizes the 3 Ps (Praise, Paraphrase, and Point-out-Behavior). The training initially focuses on parenting skills including giving attention to the child's positive behaviors and ignoring minor misbehaviors. The second phase of training includes teaching techniques for giving children effective commands to set age-appropriate limits. The PriCARE curriculum also includes trauma and stress education components in order to contextualize the use of these skills with the types of behaviors and problems demonstrated by many children who have experienced psychosocial adversity and chronic familial stress. Throughout the curriculum, caregivers are encouraged to practice the skills. PriCARE has been evaluated in the primary care setting and has shown promise. There have been limited studies on PriCARE for foster caregivers.
Study NCT03969251 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (rTMS)
Description: active high frequency repetitive TMS of left Dorsolateral Prefrontal Cortex
Study NCT03969251 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham (SS)
Description: repetitive sham rTMS
Study NCT03180086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breast cancer risk report
Description: An individualized report will inform women of their 5-year breast cancer risk using BCRAT or Tice (when breast density is available from a past mammogram), whichever is higher, and the average 5-year risk for women their age. The report will present 5-year risk as a frequency and in a pictograph and it will describe what experts recommend in terms of mammography screening, breast cancer prevention medications, breast MRIs, and BRCA testing, for women in their 40s based on their risk.
Study NCT01290471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U3-1565
Description: U3 1565 will be provided as a sterile, frozen solution. Each glass vial will contain 1.1 mL (1 mL extractable) of study medication with a concentration of 100 mg/mL. U3 1565 will be diluted in a final volume of 100 mL and administered by continuous IV infusion over 60 minutes. Infusion times can be extended to a maximum of 120 minutes for subjects unable to tolerate the 60 minute infusion.
Study NCT01607866 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Superficial parotidectomy
Description: Excision of the whole superficial lobe of the parotid gland
Study NCT04434222 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compressive stockings
Description: Compressive stockings with built in Orthotimer Sensor
Study NCT00597025 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein Food Bar Intelligent Indulgence
Description: Patients will be given one protein bar at each dialysis treatment, 3 times per week for 3 months
Study NCT00597025 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein Food Bar Intelligent Indulgence
Description: Patients will be given 7 bars per week. In addition to the the three bars given on Hemodialysis each week, the patients will be given on the first treatment of the week four protein bars to be eaten on non-dialysis days
Study NCT00597025 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein Food Bar Intelligent Indulgence
Description: Patients will be given a monthly supply of protein bars to provide for daily intake of one protein bar.
Study NCT02547779 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Saline
Description: 0.9% Saline will be used whenever an isotonic crystalloid is ordered
Study NCT02547779 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiologically-balanced isotonic crystalloid
Description: Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered
Study NCT05531591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole Augmentation
Description: Augment current antidepressant treatment with aripiprazole (tablets). Start at 2 mg daily; increase every two weeks (i.e., to 5, 7, 10 mg) to a maximum of 15 mg daily based on symptom severity and side effects.
Study NCT05531591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion Augmentation
Description: Augment current antidepressant treatment with bupropion once-daily extended release, starting at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.
Study NCT05531591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switch to bupropion
Description: Taper from current antidepressant therapy. Start bupropion once-daily extended release at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.
Study NCT05531591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Augmentation
Description: Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 meQ/L.
Study NCT05531591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switch to nortriptyline
Description: Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml
Study NCT03747939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast (CC-10004)
Description: Subjects randomized to apremilast will receive dose-titration for the initial 5 days. Apremilast subjects will receive dummy titration at wk. 16 (for early escape subjects) and again at week 24 to maintain the blinding of the original treatment assignments. Investigational product (IP) will be dispensed in blinded dose cards until Week 28. Thereafter, IP will be dispensed in open-label bottles.
Study NCT03747939 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Apremilast (CC-10004) Placebo
Description: Subjects randomized to placebo will receive dummy dose-titration for the initial 5 days. Placebo subjects who meet the criteria for early escape at wk. 16 may receive apremilast beginning at wk. 16 and will receive active titration. Remaining placebo subjects will receive active dose titration at week 24. Beginning at wk 24 all subjects will be dispensed active apremilast. Investigational product will be dispensed in blinded dose cards until Week 28. to maintain the blinding of the original treatment assignments. Thereafter, IP will be dispensed in open-label bottles
Study NCT02143401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02143401 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: Given PO
Study NCT02143401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02143401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Given PO
Study NCT02143401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study NCT02076139 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nyaditum resae® 10e4
Study NCT02076139 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nyaditum resae® 10e5
Study NCT02076139 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water
Study NCT00291928 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part A
Description: Part A Cohort 1: HuMax-CD20 300 mg at Days 0 and 14 or Placebo at Days 0 and 14 Cohort 2: HuMax-CD20 700 mg at Days 0 and 14 or Placebo at Days 0 and 14 Cohort 3: HuMax-CD20 1000 mg at Days 0 and 14 or Placebo at Days 0 and 14
Study NCT00291928 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part B
Description: Part B Group 1: HuMax-CD20 300 mg at Days 0 and 14 Group 2: HuMax-CD20 700 mg at Days 0 and 14 Group 3: HuMax-CD20 1000 mg at Days 0 and 14 Group 4: Placebo at Days 0 and 14
Study NCT02686983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone and local anesthetic
Description: Infiltration of the greater occipital nerve .
Study NCT02686983 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Betamethasone and local anesthetic
Description: Infiltration of the greater occipital nerve .
Study NCT01525875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Oxide
Description: Part 1: 1000 mg elemental magnesium (given as one 800 mg capsule of magnesium oxide two times daily).~Part 2: 1500 mg elemental magnesium (given as two 500 mg capsules of magnesium oxide in the morning and three 500 mg capsules of magnesium oxide in the evening).
Study NCT01525875 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1000 mg (one 500 mg capsule two times daily) of placebo.
Study NCT00718744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardization of allergenic extract (Ch. arcuatus)
Description: Allergenic extract for cutaneous prick-test
Study NCT00700999 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paroxetine
Description: Paroxetine 20-40mg po QD for 12 weeks
Study NCT01864200 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Crotalidae polyvalent immune fab (ovine)
Description: crotalidae antivenom
Study NCT01864200 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline placebo
Study NCT05256758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate Capsules
Description: 49 patients randomised to receive fenofibrate for 6 months.
Study NCT05256758 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placental Lactogen
Description: 13 patients randomised to receive placebo for 6 months.
Study NCT01815255 — intervention group
Intervention type: DRUG
Intervention: tenofovir (TDF)
Study NCT04172571 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK105
Description: Anti-PD-1 antibody; IV infusion, 200 mg Q3W
Study NCT04172571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: multi-targeted receptor TKI; oral administration; every 3 weeks as one cycle administered as 2 weeks on/1 week off
Study NCT02147977 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: olive oil
Study NCT01641640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg tablet administered orally once daily
Study NCT01641640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study NCT01641640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG
Description: Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
Study NCT02507739 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: no possibility to walk during labor
Study NCT02507739 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: possibility to walk during labor
Study NCT01541176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Absence of corticotherapy post-transplantation
Description: No study treatment
Study NCT02641327 — intervention group
Intervention type: DEVICE
Intervention: EarlySense (Passive monitoring)
Description: Passive contact-free monitoring
Study NCT04079218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Vaginal Insert
Description: Using a pre-loaded single-use plastic applicator, participants will insert one 10 microgram estradiol tablet intravaginally daily for 2 weeks and then one tablet twice weekly for the remainder of the study for a total of 12 weeks.
Study NCT02401152 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sports drink 1
Description: Sports drink with a specific source of CHO.
Study NCT02401152 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sports drink 2
Description: Sports drink with a specific source of CHO
Study NCT02401152 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: iso-caloric sports drink with maltodextrin as CHO source
Study NCT02939677 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Targeted exercise
Description: 12 weeks of targeted and supervised exercise intervention vs. care as usual (home based exercises)
Study NCT06700382 — intervention group
Intervention type: DRUG
Intervention: capecitabine
Description: different methods of treatment for capecitabine
Study NCT04150172 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rebamipide SR 150mg
Description: Test drug
Study NCT04150172 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rebamipide IR 100mg
Description: Reference Drug
Study NCT01024127 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01971398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive FASD education brochure
Description: Exposure to a positive FASD education brochure
Study NCT01971398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Negative FASD education brochure
Description: Exposure to a negative FASD education brochure
Study NCT01971398 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator (a general women's health brochure)
Description: Exposure to a general women's health brochure
Study NCT00698529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-face training
Description: NGOs will receive the POL intervention through face-to-face training. Staff will receive 2-day training on the POL intervention and individualized telephone follow-up consultations concerning POL implementation.
Study NCT00698529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distance training
Description: NGOs will receive the POL intervention through Web-based training. Staff will receive training delivered entirely by means of a Web-based, distance learning curriculum and through individualized telephone follow-up consultations concerning POL implementation.
Study NCT00698529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Popular Opinion Leader (POL)
Description: POL is a community-level HIV intervention that recruits and trains opinion leaders in the community to promote safe sex behaviors through risk-reduction conversations with peers.
Study NCT00659646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gentamicin-collagen sponge and levofloxacin
Description: Topical Gentamicin Collagen Sponge: 10 × 10 cm in size And 750 mg tablet po every 24 hours or 750 mg IV administered by slow infusion over 90 minutes every 24 hours.
Study NCT00659646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin only
Description: levofloxacin, 750 mg tablet po every 24 hours or 750 mg IV administered by slow infusion over 90 minutes every 24 hours
Study NCT01541176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticotherapy post-transplantation
Description: Prednisone or prednisolone orally for at least one year post-transplantation with the following minimal doses :~* D1 to D14 : 20 mg/day,~* D15 to M1 : 15 mg/day,~* M1 to M3 : 10 mg/day,~* M3 to M12 : 5 mg/day.
Study NCT02855502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Study NCT02855502 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02919865 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MR perfusion imaging
Description: MR perfusion imaging will be performed in addition to the routine neuronavigational sequence obtained from re-operative/therapy planning.~Following MR examination, patient may undergo a surgical biopsy or excision as determined clinically by the neurosurgeon.~All patients, including those who do not go to surgery, will undergo clinical follow-up and imaging follow-up with perfusion imaging. This will allow for assessment of lesion progression over time, yielding valuable diagnostic information in differentiating radiation necrosis from tumour recurrence, particularly in those patients who do not undergo surgery.
Study NCT04182542 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency
Description: The volunteers will receive radiofrequency (TECAR-BTL® device, with epidermal temperature above 40ºC) in the right infraumbilical abdominal region, with an application time of 10 minutes (2 minutes per applicator area) and the left region will be used as control. A single session will be held. After approximately 30 days of this application the material for histological analysis will be collected during the surgical act, at which point the skin and the subcutaneous tissue of the infraumbilical region are discarded by the surgeon.
Study NCT00237718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha, gamma, beta, and delta (mixed) tocopherols
Description: approximately 666 IU daily (1 pill) for 6 months
Study NCT00237718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha lipoic acid
Description: 600 mg daily (2 pills 300 mg each) for 6 months
Study NCT00237718 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo for alpha, gamma, beta, and delta (mixed) tocopherols; 1 pill daily for 6 months
Study NCT00237718 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo for alpha lipoic acid; 2 pills daily for 6 months
Study NCT03756896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV
Study NCT03756896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT03756896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given PO
Study NCT01733199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaires
Description: Summons of patients and filling questionnaire.
Study NCT01615523 — intervention group
Intervention type: OTHER
Intervention: MRI, EEG and cognitive testing
Description: Sleep EEG and one MRI, executive function testing using Strrop test, BRIEF questionnaire and CantabEclipse
Study NCT03444155 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Natural Panmol-B-Complex
Description: Natural Panmol-B-Complex: B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg) - Synthetic Vitamin B-Complex - B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg)
Study NCT03444155 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Synthetic Vitamin B-Complex
Description: Synthetic Vitamin B-Complex: B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85µg) - Natural Panmol-B-Complex: B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg)
Study NCT00578929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine Hydrochloride Nasal Spray 0.6%
Description: Olopatadine HCl 1 or 2 sprays per nostril twice daily
Study NCT00578929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle 1 or 2 sprays per nostril twice daily
Study NCT01657201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYP-1018 200mg
Description: SYP-1018 200mg, Intravenous administration
Study NCT01657201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole 200mg
Description: Voriconazole 200mg, Intravenous administration
Study NCT02784418 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chronic Total Occlusion Percutaneous Coronary Intervention
Description: Chronic Total Occlusion Percutaneous Coronary Intervention (CTO PCI), as per standard clinical practice
Study NCT02784418 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: Sham Procedure: Bilateral arterial access, without angiography or PCI being performed
Study NCT02535598 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Normal presentation
Description: All the material will be presented as plain text.
Study NCT01256775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NCX-4016
Description: NCX4016 800 mg b.i.d. for 6 months on top of aspirin 100 mg o.d.
Study NCT01256775 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NCX4016 placebo
Description: NCX4016 placebo b.i.d. for 6 months
Study NCT02453113 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: low power laser
Description: Signaling in Human Skin Associated with Low-Power, Infrared Laser Treatment
Study NCT02348138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric handgrip training
Description: The two experimental groups (HBT and ST) will receive intervention with isometric handgrip exercise for 12 weeks, and the HBT group without daily supervision.
Study NCT03309436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate protocol
Description: Take CC 100mg/d at the same time with Gn until hCG injection.
Study NCT03309436 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Procedure
Description: When a dominant follicle diameter over 14mm or serum E2 over 350pg/ml, use GnRH-ant 0.25mg/d, until hCG injection.